Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 45,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $41.43 on Friday. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $43.29. The firm has a 50 day moving average price of $36.81 and a 200 day moving average price of $24.70. The company has a market cap of $1.99 billion and a price-to-earnings ratio of -1.98.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Analysts Set New Price Targets

MAZE has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. HC Wainwright raised their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Guggenheim reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. Finally, BTIG Research increased their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.38.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the period. Legal & General Group Plc grew its stake in shares of Maze Therapeutics by 23.0% during the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after acquiring an additional 977 shares in the last quarter. Bank of America Corp DE increased its position in shares of Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after acquiring an additional 1,455 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics in the third quarter worth about $52,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analysts have been raising ratings and targets (consensus remains a “Buy”, average PT ≈ $43.38), supporting upside expectations. Analyst Ratings/Targets
• Positive Sentiment: Several institutions have increased or initiated stakes (e.g., Vanguard, Frazier, ARCH, Marshall Wace), indicating institutional interest that can underpin the stock. Institutional Ownership Details
• Neutral Sentiment: Recent Q3/Q4 results showed an EPS beat (reported -$0.66 vs. -$0.74 consensus), which is supportive but the company remains unprofitable and clinical-stage. Earnings Summary
• Neutral Sentiment: A de‑minimis sale of 100 shares by insider Atul Dandekar (Dec. 30) is immaterial on its own. Small Form 4
• Negative Sentiment: Atul Dandekar sold 72,400 shares (~$2.94M at ~$40.56) and reduced his stake by ~87.3% — the largest and most sentiment‑negative transaction reported. Dandekar Form 4
• Negative Sentiment: CMO Harold Bernstein sold 45,000 shares (~$1.83M at ~$40.56). Large C‑suite sales can raise questions on insider conviction and add selling pressure. Bernstein Form 4
• Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (~$606K combined; sales at ~$40.58 and ~$40.08), materially reducing her stake. Multiple insider sales may weigh on near‑term sentiment. Bachrodt Form 4

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.